Satyanarayana R Pondugula

Dr. Satyanarayana R Pondugula

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Cancer Letters
Verified
Journal Article
Closed access
SPSatyanarayana R Pondugula
Satyanarayana R Pondugula
SMSridhar Mani
Sridhar Mani

1 April 2009 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
SPSatyanarayana R Pondugula
Satyanarayana R Pondugula
CBCynthia Brimer-Cline
Cynthia Brimer-Cline
JWJing Wu
Jing Wu
ESErin G. Schuetz
Erin G. Schuetz
RTRakesh K. Tyagi
Rakesh K. Tyagi
TCTaosheng Chen
Taosheng Chen
The pregnane X receptor (PXR) plays crucial roles in multiple physiological processes. However, the signaling mechanisms responsible are not well defined; it is most likely that multiple functions of PXR are modulated by its phosphorylation. Therefore, we sought to determine whether mutation at a highly conserved Thr57 affects human PXR (hPXR) function. Site-directed mutagenesis was performed to generate phosphorylation-deficient (hPXRT57A) and phosphomimetic (hPXRT57D) mutants. Gene reporter, Western blotting, immunocytochemistry, mammalian two-hybrid, and electrophoretic mobility shift assays were used to study cytochrome P450 3A4 (CYP3A4) promoter activation, protein levels, localization, cofactor interaction, and CYP3A4 promoter binding of the hPXR mutants, respectively. hPXRT57D, but not hPXRT57A, lost its transcriptional activity. Neither mutation altered hPXR9s protein levels and interaction with steroid receptor coactivator-1. hPXR and hPXRT57A exhibited a homogenous nuclear distribution, whereas hPXRT57D exhibited a distinctive punctate nuclear localization pattern similar to that of hPXR mutants with impaired function that colocalize with silencing mediator of retinoid and thyroid receptors (SMRT), although silencing of SMRT did not rescue the altered function of hPXRT57D. However, hPXRT57D, but not hPXRT57A, impaired hPXR9s ability to bind to the CYP3A4 promoter, consistent with the mutant9s transactivation function. Furthermore, the 70-kDa form of ribosomal protein S6 kinase (p70 S6K) phosphorylated hPXR in vitro and inhibited its transcriptional activity, whereas hPXRT57A partially resisted the inhibitory effect of p70 S6K. Our studies identify a functionally significant phosphomimetic mutant (hPXRT57D) and show p70 S6K phosphorylation and regulation of hPXR transactivation to support the notion that phosphorylation plays important roles in regulating hPXR function.

8 June 2009 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
SPSatyanarayana R Pondugula
Satyanarayana R Pondugula
HDHanqing Dong
Hanqing Dong
TCTaosheng Chen
Taosheng Chen
(2009). Phosphorylation and protein–protein interactions in PXR-mediated CYP3A repression. Expert Opinion on Drug Metabolism & Toxicology: Vol. 5, No. 8, pp. 861-873.

1 March 2009 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
SKSung Huhn Kim
Sung Huhn Kim
KKKyunghee X. Kim
Kyunghee X. Kim
NRNithya N. Raveendran
Nithya N. Raveendran
TWTao Wu
Tao Wu
SPSatyanarayana R Pondugula
Satyanarayana R Pondugula
DMDaniel C. Marcus
Daniel C. Marcus
Reissner's membrane epithelium forms much of the barrier that produces and sustains the large ionic differences between cochlear endolymph and perilymph. We have reported that Reissner's membrane contributes to normal cochlear function by absorbing Na+from endolymph via amiloride-sensitive channels in gerbil inner ear. We used mouse Reissner's membrane to 1) identify candidate genes involved in the Na+transport pathway, 2) determine whether their level of expression was regulated by the synthetic glucocorticoid dexamethasone, and 3) obtain functional evidence for the physiological importance of these genes. Transcripts were present for α-, β-, and γ-subunits of epithelial Na+channel (ENaC); corticosteroid receptors GR (glucocorticoid receptor) and MR (mineralocorticoid receptor); GR agonist regulator 11β-hydroxysteroid dehydrogenase (HSD) type 1 (11β-HSD1); Na+transport control components SGK1, Nedd4-2, and WNKs; and K+channels and Na+-K+-ATPase. Expression of the MR agonist regulator 11β-HSD2 was not detected. Dexamethasone upregulated transcripts for α- and β-subunits of ENaC (∼6- and ∼3-fold), KCNK1 (∼3-fold), 11β-HSD1 (∼2-fold), SGK1 (∼2-fold), and WNK4 (∼3-fold). Transepithelial currents from the apical to the basolateral side of Reissner's membrane were sensitive to amiloride (IC50∼0.7 μM) and benzamil (IC50∼0.1 μM), but not EIPA (IC50∼34 μM); amiloride-blocked transepithelial current was not immediately changed by forskolin/IBMX. Currents were reduced by ouabain, lowered bath Na+concentration (from 150 to 120 mM), and K+channel blockers (XE-991, Ba2+, and acidification from pH 7.4 to 6.5). Dexamethasone-stimulated current and gene expression were reduced by mifepristone, but not spironolactone. These molecular, pharmacological, and functional observations are consistent with Na+absorption by mouse Reissner's membrane, which is mediated by apical ENaC and/or other amiloride-sensitive channels, basolateral Na+-K+-ATPase, and K+-permeable channels and is under the control of glucocorticoids. These results provide an understanding and a molecular definition of an important transport function of Reissner's membrane epithelium in the homeostasis of cochlear endolymph.

1 June 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DYDaisuke Yamauchi
Daisuke Yamauchi
NRNithya N. Raveendran
Nithya N. Raveendran
SPSatyanarayana R Pondugula
Satyanarayana R Pondugula
SKSuresh B. Kampalli
Suresh B. Kampalli
JSJoel D. Sanneman
Joel D. Sanneman
DMDaniel C. Marcus
Daniel C. Marcus

12 June 2016 in Nuclear Receptor Research
Verified
Journal Article
Open access
PDF file
SPSatyanarayana R Pondugula
Satyanarayana R Pondugula
PPPetr Pavek
Petr Pavek
SMSridhar Mani
Sridhar Mani
Pregnane X receptor (PXR) is an adopted orphan nuclear receptor that is activated by a wide-range of endobiotics and xenobiotics, including chemotherapy drugs. PXR plays a major role in the metabolism and clearance of xenobiotics and endobiotics in liver and intestine via induction of drug-metabolizing enzymes and drug-transporting proteins. However, PXR is expressed in several cancer tissues and the accumulating evidence strongly points to the differential role of PXR in cancer growth and progression as well as in chemotherapy outcome. In cancer cells, besides regulating the gene expression of enzymes and proteins involved in drug metabolism and transport, PXR also regulates other genes involved in proliferation, metastasis, apoptosis, anti-apoptosis, inflammation, and oxidative stress. In this review, we focus on the differential role of PXR in a variety of cancers, including prostate, breast, ovarian, endometrial, and colon. We also discuss the future directions to further understand the differential role of PXR in cancer, and conclude with the need to identify novel selective PXR modulators to target PXR in PXR-expressing cancers.